EcoDrugPlus

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSAPOG00000001020
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSAPOG00000018148
Gene Symbol: OPRK1
3 Cross references
196 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSAPOG00000016876
Gene Symbol: OXTR
3 Cross references
186 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSAPOG00000020692
Gene Symbol: PTH1R
3 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSAPOG00000006313
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSAPOG00000011538
Gene Symbol: PPARG
4 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSAPOG00000018560
Gene Symbol: LOC110959608
3 Cross references
397 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSAPOG00000002416
Gene Symbol: LOC110953589
3 Cross references
384 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha

Ensembl ID : ENSAPOG00000012655
Gene Symbol: LOC110953301
3 Cross references
203 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSAPOG00000002241
Gene Symbol: LOC110964163
3 Cross references
197 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma

Ensembl ID : ENSAPOG00000012304
Gene Symbol: LOC110964517
2 Cross references
187 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSAPOG00000003603
Gene Symbol: LOC110972358
2 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).